Zobrazeno 1 - 10
of 22
pro vyhledávání: '"A R, Koomen"'
Autor:
Lisanne L Krens, Lieke H J Simkens, Jara M Baas, Els R Koomen, Hans Gelderblom, Cornelis J A Punt, Henk-Jan Guchelaar
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e112201 (2014)
Statins may inhibit the expression of the mutant KRAS phenotype by preventing the prenylation and thus the activation of the KRAS protein. This study was aimed at retrospectively evaluating the effect of statin use on outcome in KRAS mutant metastati
Externí odkaz:
https://doaj.org/article/4bae879e573f4de885ab3d341ec5b762
Publikováno v:
Cancer Epidemiology, 33(5), 391-395. Elsevier BV
Koomen, E R, Herings, R M, Guchelaar, H J & Nijsten, T 2009, ' Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers ', Cancer Epidemiology, vol. 33, no. 5, pp. 391-395 . https://doi.org/10.1016/j.canep.2009.10.005
Koomen, E R, Herings, R M, Guchelaar, H J & Nijsten, T 2009, ' Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers ', Cancer Epidemiology, vol. 33, no. 5, pp. 391-395 . https://doi.org/10.1016/j.canep.2009.10.005
A reduced incidence of nonmelanoma skin cancer among users of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARb) has been reported. A similar effect is suggested for cutaneous melanoma. We aimed to investigate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::436ce1922500f9df3bd52e9ccb4e150b
https://www.ncbi.nlm.nih.gov/pubmed/19896919
https://www.ncbi.nlm.nih.gov/pubmed/19896919
Autor:
Henk-Jan Guchelaar, Els R. Koomen, Cornelis J. A. Punt, J. M. Baas, Hans Gelderblom, L. L. Krens, Lieke H.J. Simkens
Publikováno v:
PLoS ONE, 9(11). Public Library of Science
PLoS ONE, Vol 9, Iss 11, p e112201 (2014)
PLoS ONE
PLoS ONE, 9(11)
PLoS ONE, Vol 9, Iss 11, p e112201 (2014)
PLoS ONE
PLoS ONE, 9(11)
Statins may inhibit the expression of the mutant KRAS phenotype by preventing the prenylation and thus the activation of the KRAS protein. This study was aimed at retrospectively evaluating the effect of statin use on outcome in KRAS mutant metastati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d106c50241a1fc51f7f78349081bc36d
https://pure.amc.nl/en/publications/statin-use-is-not-associated-with-improved-progression-free-survival-in-cetuximab-treated-kras-mutant-metastatic-colorectal-cancer-patients-results-from-the-cairo2-study(24e30aaf-f4ac-43b5-96f3-906df773970f).html
https://pure.amc.nl/en/publications/statin-use-is-not-associated-with-improved-progression-free-survival-in-cetuximab-treated-kras-mutant-metastatic-colorectal-cancer-patients-results-from-the-cairo2-study(24e30aaf-f4ac-43b5-96f3-906df773970f).html
Publikováno v:
British Journal of Cancer
In an observational follow-up study we determined whether the combined use of mammography and breast ultrasonography is an appropriate diagnostic tool to select patients with symptomatic breast disease who need additional pathological evaluation. Mam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02ca0a0ef4dac6d77098938ec9793d79
http://europepmc.org/articles/PMC2224070
http://europepmc.org/articles/PMC2224070
Autor:
Henk-Jan Guchelaar, Ron M. C. Herings, Loes E. Visser, Tamar Nijsten, Satu J. Siiskonen, Bruno H. Ch. Stricker, Els R. Koomen
Publikováno v:
Siiskonen, S J, Koomen, E R, Visser, L E, Herings, R M C, Guchelaar, H J, Stricker, B H C & Nijsten, T E C 2013, ' Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma ', European Journal of Clinical Pharmacology, vol. 69, no. 7, pp. 1437-1444 . https://doi.org/10.1007/s00228-013-1476-x
European Journal of Clinical Pharmacology, 69(7), 1437-1444. Springer Verlag
European Journal of Clinical Pharmacology, 69(7), 1437-1444
European Journal of Clinical Pharmacology, 69(7), 1437-1444. Springer-Verlag
European Journal of Clinical Pharmacology, 69(7), 1437-1444. Springer Verlag
European Journal of Clinical Pharmacology, 69(7), 1437-1444
European Journal of Clinical Pharmacology, 69(7), 1437-1444. Springer-Verlag
Purpose: Ultraviolet radiation exposure is the most important exogenous risk factor for cutaneous malignancies. It is possible that phototoxic drugs promote the development of cutaneous melanoma (CM) by intensifying the effect of ultraviolet light on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3313ebb74eacc6891eb78e03d59b209
https://pubmed.ncbi.nlm.nih.gov/23471440
https://pubmed.ncbi.nlm.nih.gov/23471440
Publikováno v:
Archives of Dermatology-Chicago-, 148(5), 638-640
Archives of Dermatology, 148(5), 638-640. American Medical Association
JNCI Journal of the National Cancer Institute
Archives of Dermatology, 148(5), 638-640. American Medical Association
JNCI Journal of the National Cancer Institute
Background Preclinical studies indicate that the enzyme cyclooxygenase 2 plays an important role in ultraviolet-induced skin cancers. We evaluated the efficacy and safety of celecoxib, a cyclooxygenase 2 inhibitor, as a chemopreventive agent for acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a27a7172f595fd273d81796307b0c01c
https://hdl.handle.net/1887/99048
https://hdl.handle.net/1887/99048
Hormonal and reproductive factors in relation to melanoma in women: Current review and meta-analysis
Autor:
Saverio Caini, Sara Gandini, Francesco Sera, Alessandra di Pietro, Els R. Koomen, Simona Iodice
Publikováno v:
European Journal of Cancer, 47(17), 2607-2617
A number of studies have focused on possible relationships between characteristics of female endocrine status and melanoma (CM) risk; however, the link between melanoma, oral contraceptive (OC) and hormonal replacement therapy (HRT) use, and reproduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2b34567b8a023d7ecbbd68c04a46b9f
https://doi.org/10.1016/j.ejca.2011.04.023
https://doi.org/10.1016/j.ejca.2011.04.023
Autor:
Marieke W. J. Louwman, Tamar Nijsten, Esther de Vries, Jan Willem Coebergh, Alexander C.J. van Akkooi, Els R. Koomen, Léon C van Kempen, Henk-Jan Guchelaar
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention, 19, 6, pp. 1453-9
Cancer Epidemiology, Biomarkers & Prevention, 19, 1453-9
Cancer Epidemiology, Biomarkers and Prevention, 19(6), 1453-1459
Cancer Epidemiology Biomarkers & Prevention, 19(6), 1453-1459. American Association for Cancer Research Inc.
Cancer Epidemiology, Biomarkers & Prevention, 19, 1453-9
Cancer Epidemiology, Biomarkers and Prevention, 19(6), 1453-1459
Cancer Epidemiology Biomarkers & Prevention, 19(6), 1453-1459. American Association for Cancer Research Inc.
Background: Reliable population-based incidence and survival data on extracutaneous melanoma (ECM) are sparse. Methods: Incidence data (1989-2006) from the Netherlands Cancer Registry were combined with vital status on January 1, 2008. Age-adjusted a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed8772b84eb9d858abc08b442710de70
https://hdl.handle.net/2066/88690
https://hdl.handle.net/2066/88690
Autor:
Tamar Nijsten, Henk-Jan Guchelaar, Mariel K. Casparie, Ron M. C. Herings, Arjen Joosse, Elsje R. Koomen
Publikováno v:
Melanoma Research, 19(5), 327-332. Lippincott Williams and Wilkins
Koomen, E R, Joosse, A, Herings, R M, Casparie, M K, Guchelaar, H J & Nijsten, T 2009, ' Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy ', Melanoma Research, vol. 19, no. 5, pp. 327-332 . https://doi.org/10.1097/CMR.0b013e32832f159c
Koomen, E R, Joosse, A, Herings, R M, Casparie, M K, Guchelaar, H J & Nijsten, T 2009, ' Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy ', Melanoma Research, vol. 19, no. 5, pp. 327-332 . https://doi.org/10.1097/CMR.0b013e32832f159c
Recently, we showed there was a cumulative dose-dependent association between the use of estrogens and the incidence of cutaneous melanoma (CM). This association was shown for both oral contraceptives (OC) and hormonal replacement therapy (HRT). Some
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f57802d60c755c3d131368821c5318e
https://research.vumc.nl/en/publications/fcc83246-3f62-47ed-a7e9-3110f8444391
https://research.vumc.nl/en/publications/fcc83246-3f62-47ed-a7e9-3110f8444391
Autor:
Arjen Joosse, Mariel K. Casparie, Ron M. C. Herings, Tamar Nijsten, Henk-Jan Guchelaar, Elsje R. Koomen
Publikováno v:
Annals of Oncology, 20(2), 358-364. Elsevier Ltd.
Annals of Oncology, 20(2), 358-364. Oxford University Press
Koomen, E R, Joosse, A, Herings, R M, Casparie, M K, Guchelaar, H J & Nijsten, T 2009, ' Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study ', Annals of Oncology, vol. 20, no. 2, pp. 358-364 . https://doi.org/10.1093/annonc/mdn589
Annals of Oncology, 20(2), 358-364. Oxford University Press
Koomen, E R, Joosse, A, Herings, R M, Casparie, M K, Guchelaar, H J & Nijsten, T 2009, ' Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study ', Annals of Oncology, vol. 20, no. 2, pp. 358-364 . https://doi.org/10.1093/annonc/mdn589
BACKGROUND: Multiple studies showed conflicting results on the association between oral contraceptive (OC) use and the development of cutaneous melanoma (CM). We investigated the association between estrogen use and CM incidence. PATIENTS AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dcd08505551aabcd643e082b7162bdc
https://pubmed.ncbi.nlm.nih.gov/18725391
https://pubmed.ncbi.nlm.nih.gov/18725391